Does intravenous ferric carboxymaltose improve symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency?
Intravenous ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency.
Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Anker et al. (2009) studied this question.